Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Reviewed by TrialFinderData Editorial Team · Updated

25 clinical trials · 25 recruiting · OTHER

Fondazione Policlinico Universitario Agostino Gemelli IRCCS has 25 clinical trials registered on ClinicalTrials.gov, with 25 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Fondazione Policlinico Universitario Agostino Gemelli IRCCS\'s Trial Portfolio

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

25 of Fondazione Policlinico Universitario Agostino Gemelli IRCCS's 25 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS's research footprint spans Myasthenia Gravis, Generalized (3 trials), Multiple Sclerosis (2), and rectal-neoplasm (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

is the largest single phase in Fondazione Policlinico Universitario Agostino Gemelli IRCCS's portfolio at 64% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Fondazione Policlinico Universitario Agostino Gemelli IRCCS

RECRUITINGNCT05984576

Radiotherapy & Total Neoadjuvant Therapy for Recurrent Rectal Cancer in Previously Irradiated Patients, an Italian...

The introduction of neoadjuvant chemoradiation therapy (CRT) and the use of advanced surgical techniques have led to a reduction in mortality and recurrence rates for rectal...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 881 location
Rectal Neoplasm
RECRUITINGNCT06364579

Patient Reported Outcomes (PROs) in Anal Cancer Patient Treated by Intensity Modulated Radiotherapy (IMRT).

Radiochemotherapy is the standard treatment for neoplasms of the anal canal with excellent rates of local control and preservation of the anal sphincter. However, patients may...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 1201 location
Anal Cancer Patients
RECRUITINGNCT05950503

Role of MRI in the Evaluation of Hepatic Metastases of Colorectal Cancer

This study wants to evaluate the use of MRI in the managemente of mCRC with liver only metastases.

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 1001 location
Colorectal Cancer
RECRUITINGNCT06331130

Mesenteric Infiltration in Ovarian Cancer

To evaluate if CT features at diagnosis in patients with HGSOC can be used to build an Artificial Intelligence model capable of discerning the pathological involvement of the...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 5101 location
Ovary Cancer
RECRUITINGNCT06017557

Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer

PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 1511 location
Ovarian Cancer Stage IIIOvarian Cancer Stage IV
RECRUITINGNCT05797415

Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers

The study involves enrollment of patients with sebaceous carcinoma, Merkel's carcinoma, Porocarcinoma, Melanoma, and squamous cell Ca of the ocular surface and adnexa both primary...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 251 location
Ocular Sebaceous CarcinomaOcular Basal Cell CarcinomaOcular Surface Squamous Neoplasia+3
RECRUITINGNCT06402695

Observational Study on GEP-and Pulm-NET Treated at FPG

Observational ambispective monocentric study on the clinical, laboratory, pathological and molecular characteristics of patients suffering from gastroenteropancreatic tract and...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 6501 location
Neuroendocrine TumorsGep NetPulmonary Neuroendocrine Neoplasm
RECRUITINGNCT06372587

Next-Generation alzheImer'S Therapeutics

Is this the right time to use next-generation approaches in Alzheimer's disease (AD)? In recent years, several large clinical trials testing treatments for AD have failed, putting...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 141 location
Alzheimer Disease
RECRUITINGNCT06865274

Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte...

The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD)...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 501 location
Neuromyelitis Optica Spectrum DisordersMOGADMultiple Sclerosis
RECRUITINGNCT07588971

Natural History and Prognosis of Pediatric Epilepsies With Different Etiology

Epilepsy is one of the most common neurological diseases in Italy, affecting about 500,000 people. Pediatric age represents one of the most affected groups with a consequent...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 23001 location
Pediatric Epilepsies
RECRUITINGNCT06551649

Human Amniotic Mesenchymal Cell Secretome for Neurodegeneration and Neuroinflammation

Neurodegenerative diseases are debilitating conditions characterized by chronic inflammation, leading to dysfunction of both the non-neuronal cellular components of the central...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 602 locations
Amyotrophic Lateral SclerosisMultiple Sclerosis
RECRUITINGPhase 1 / Phase 2NCT06685042

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

The CATARSIS study explores the use of anti-CD19 CAR T-cell therapy as a novel approach for treating refractory systemic autoimmune diseases, specifically SLE, SSc, DM/PM, and...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 81 location
Lupus Erythematosus, SystemicSystem; SclerosisANCA Associated Vasculitis+2
RECRUITINGPhase 3NCT05868837

Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)

The primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 401 location
Myasthenia Gravis, Generalized
RECRUITINGNCT06455709

Markers of Favorable Response to Complement Inhibitors Therapy

Myasthenia gravis is an autoimmune neurological disease caused by autoantibodies primarily directed against components of the postsynaptic membrane of the neuromuscular junction....

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 501 location
Myasthenia Gravis, Generalized
RECRUITINGNCT06685055

Markers of Favorable Response to FcRn Inhibitors(INFORM)

Myasthenia gravis is an autoimmune neurological disease caused by autoantibodies primarily directed against components of the postsynaptic membrane of the neuromuscular junction....

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 501 location
Myasthenia Gravis Generalized
RECRUITINGNCT06941584

Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies

Studying genetic predisposition in autoimmune neurological diseases could help improve diagnostic accuracy and offer new treatment possibilities

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 401 location
AIRE Deficiency
RECRUITINGNCT06879236

Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease

The prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, Metabolic dysfunction-associated steatohepatitis (MASH), is high and they...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 2521 location
NASHNAFLD
RECRUITINGNCT07440511

Spleen Stiffness Measurement for the Detection of Advanced Fibrosis

Measurement of spleen stiffness (SSM) has shown potential as a complementary tool to liver stiffness measurement (LSM) for the assessment of portal hypertension in patients with...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 5001 location
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
RECRUITINGNCT07508553

Comparison of Bone Mineral Density in the Third Trimester Between Women in Singleton and Twin Pregnancies Using...

This clinical study aims to monitor and evaluate bone mineral density and fracture risk in women with singleton and twin pregnancies through the combined use of: * two specific...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 1001 location
OsteoporosisPregnancyTwin Pregnancy
RECRUITINGNCT07541638

Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases

Connective tissue diseases (CTDs) cover a broad range of systemic rheumatic disorders characterized by abnormal immune activation, chronic inflammatory response, and fibrosis of...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 2001 location
Connective Tissue DiseasesInterstitial Lung Disease
RECRUITINGNCT06366815

phenotypeS in Non Ambulant Duchenne Muscular Dystrophy

The aims of the study are to prospectively collect information on several aspects of function in non-ambulant DMD patients by using a structured battery of tests including motor,...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 2502 locations
Duchenne Muscular DystrophyNatural HistoryMotor Function; Retardation
RECRUITINGNCT05755451

Natural History of SMA

This is an investigator initiated observational study with the aim to record several aspects of function, care and adverse events in a large cohort of SMA patients followed...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 12005 locations
Muscular Atrophy, Spinal
RECRUITINGNCT05768048

Long Term Trajectories of SMA Patients Receiving or Not Disease-modifying Treatments

This is an observational multicenter retrospective and prospective study on natural history of SMA also considering the 'new natural history' secondary to the availability of...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 5005 locations
Spinal Muscular Atrophy
RECRUITINGNCT05760287

Echocardiographic Characterization of Cardiac Amyloidosis

This is a mono-center observational ambispective study in which patients with cardiac amyloidosis evaluated at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 2551 location
Cardiac Amyloidosis
RECRUITINGNCT05929209

Exploring Biomarkers in Hereditary Transthyretin Amyloidosis

Hereditary transthyretin amyloidosis (ATTRv, v for variant) is a severe and heterogeneous systemic condition due to mutations in the transthyretin (TTR) gene. The availability of...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 801 location
Hereditary Transthyretin Amyloidosis

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Fondazione Policlinico Universitario Agostino Gemelli IRCCS have on ClinicalTrials.gov?

Fondazione Policlinico Universitario Agostino Gemelli IRCCS has 25 clinical trials registered on the federal ClinicalTrials.gov registry, of which 25 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Fondazione Policlinico Universitario Agostino Gemelli IRCCS study?

Fondazione Policlinico Universitario Agostino Gemelli IRCCS's registered trials cover 20 conditions on ClinicalTrials.gov, led by Myasthenia Gravis, Generalized (3 trials), Multiple Sclerosis (2 trials), rectal-neoplasm (1 trial), anal-cancer-patients (1 trial), Colorectal Cancer (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Fondazione Policlinico Universitario Agostino Gemelli IRCCS clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 25 trials tracked for Fondazione Policlinico Universitario Agostino Gemelli IRCCS.